By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- New research on Biotechnology is the subject of a report. According to news reporting out of Lexington, Massachusetts, by NewsRx editors, research stated, "Epithelial ovarian cancer (EOC) is usually detected at an advanced stage and is frequently lethal. Although many patients respond to initial surgery and standard chemotherapy consisting of a platinum-based agent and a taxane, most experience recurrence and eventually treatment-resistant disease."
Our news journalists obtained a quote from the research from Synta Pharmaceuticals Corp, "Although there have been numerous efforts to apply protein-targeted agents in EOC, these studies have so far documented little efficacy. Our goal was to identify broadly susceptible signaling proteins or pathways in EOC. As a new approach, we conducted data-mining meta-analyses integrating results from multiple siRNA screens to identify gene targets that showed significant inhibition of cell growth. On the basis of this meta-analysis, we established that many genes with such activity were clients of the protein chaperone HSP90. We therefore assessed ganetespib, a clinically promising second-generation small-molecule HSP90 inhibitor, for activity against EOC, both as a single agent and in combination with cytotoxic and targeted therapeutic agents. Ganetespib significantly reduced cell growth, induced cell-cycle arrest and apoptosis in vitro, inhibited growth of orthotopic xenografts and spontaneous ovarian tumors in transgenic mice in vivo, and inhibited expression and activation of numerous proteins linked to EOC progression. Importantly, paclitaxel significantly potentiated ganetespib activity in cultured cells and tumors. Moreover, combined treatment of cells with ganetespib and siRNAs or small molecules inhibiting genes identified in the meta-analysis in several cases resulted in enhanced activity."
According to the news editors, the research concluded: "These results strongly support investigation of ganetespib, a single-targeted agent with effects on numerous proteins and pathways, in augmenting standard EOC therapies."
For more information on this research see: Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer. Clinical Cancer Research, 2013;19(18):5053-5067. Clinical Cancer Research can be contacted at: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA. (American Association for Cancer Research - www.aacr.com; Clinical Cancer Research - clincancerres.aacrjournals.org/)
Our news journalists report that additional information may be obtained by contacting H.Q. Liu, Synta Pharmaceut Corp, Lexington, MA, United States. Additional authors for this research include F. Xiao, I.G. Serebriiskii, S.W. O'Brien, M.A. Maglaty, I. Astsaturov, S. Litwin, L.P. Martin, D.A. Proia, E.A. Golemis and D.C. Connolly (see also technology.html">Biotechnology).
Keywords for this news article include: Biotechnology, Drugs, Genetics, Oncology, Peptides, Proteins, Lexington, Treatment, Gynecology, Amino Acids, Chemotherapy, Massachusetts, United States, Women's Health, Cancer Gene Therapy, North and Central America, Epithelial Ovarian Cancer
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC